NorthRock Partners LLC Takes Position in IQVIA Holdings Inc. (NYSE:IQV)

NorthRock Partners LLC acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 2,020 shares of the medical research company's stock, valued at approximately $397,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of IQV. Synergy Asset Management LLC acquired a new stake in shares of IQVIA during the fourth quarter valued at about $33,000. GKV Capital Management Co. Inc. purchased a new position in shares of IQVIA during the fourth quarter worth $39,000. Lee Danner & Bass Inc. acquired a new stake in shares of IQVIA in the fourth quarter valued at $44,000. Zions Bancorporation N.A. raised its holdings in shares of IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after buying an additional 85 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new position in IQVIA during the 4th quarter worth about $60,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Down 0.4%

IQVIA stock traded down $0.52 during mid-day trading on Thursday, hitting $136.77. The company had a trading volume of 1,047,237 shares, compared to its average volume of 1,541,710. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 1 year low of $135.77 and a 1 year high of $252.88. The business has a fifty day moving average of $157.30 and a 200 day moving average of $184.65. The stock has a market cap of $23.66 billion, a price-to-earnings ratio of 18.22, a PEG ratio of 1.99 and a beta of 1.34.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The firm had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. During the same period last year, the firm posted $2.54 EPS. The company's revenue was up 2.5% on a year-over-year basis. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on IQV shares. BTIG Research lowered shares of IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and dropped their price objective for the company from $260.00 to $160.00 in a report on Friday, April 25th. Hsbc Global Res lowered shares of IQVIA from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Citigroup decreased their price target on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. Eight analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $228.14.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.